Parkview Laboratory: Test Directory

Requisition must be completed with the following information: patient’s first and last name, patient’s DOB, last four digits of the patient’s SSN, practitioner’s name and signature, ICD-10 code, the patient’s billing information and menopausal Status, DATE & TIME OF COLLECTION

Ensure tube is labeled and document the date and time of collection

Mix the blood by inverting 5 times. 

Specimen must be spun within 2 hours of collection. 

Allow specimen to clot for 30 min but no longer than 2 hours. 

Once specimen has clotted, centrifuge at1000-1300 x RCF for 10-15 minutes. (The important factor is that the gel barrier separates the cells from the serum within 2 hours and that the serum is free of fibrin particles (globs). If not, the specimen should be spun again in attempt to clarify the sample.)

.

Patients with an elevated risk of malignancy may benefit from a consultation with a gynecologic oncologist.

In the prospective study, Bristow, et al. published a histogram showing the observed risk of malignancy associated with respective OVA1 (MIA) scores for premenopausal and postmenopausal women⁵

OVA1/MIA combines the results of five immunoassays associated with ovarian cancer (CA 125 II, transferrin, transthyretin [prealbumin], apolipoprotein A-1, and β 2-microglobulin) into a numerical score of 0-10 using a proprietary algorithm. OVA1/MIA is intended for use in combination with a physician assessment and imaging results, and to ultimately increase the number of patients detected in an early stage and to more effectively manage the number of patients with a low risk of malignancy being referred to gynecologic oncologists.